The trial randomized individuals who had fasting plasma glucose concentrations >6 and <15 mmol / L (>108 and <270 mg / dL) to receive either a conventional glycemic-control strategy (primarily with diet) or an intensive glycemic-control strategy, primarily with monotherapy with sulfonylurea, insulin, or (only for those with >120% of ideal body weight) metformin.